Lysosomal Storage Diseases Market : TOC


  • Published On : Oct-2016 |
  • Pages : 167 Pages |
  • Format :

1. Executive Summary

2. Market Introduction
   2.1. Market Definition
   2.2. Market Taxonomy

3. Global Lysosomal Storage Diseases Therapeutics Market Analysis Scenario
   3.1. Market Size (US$ Mn) and Forecast
        3.1.1. Market Size and Y-o-Y Growth
        3.1.2. Absolute $ Opportunity

4. Market Dynamics
   4.1. Macro-economic Factors
   4.2. Drivers
   4.3. Restraints
   4.4. Opportunity
   4.5.Forecast Factors – Relevance and Impact
   4.6. Reimbursement Scenario in U.S.
   4.7. Pipeline Analysis

5. Global Lysosomal Storage Diseases Therapeutics Market Analysis and Forecasts, By Therapy
   5.1. Introduction
   5.2. Basis Point Share (BPS) Analysis By Therapy Type
   5.3. Y-o-Y Growth Projections By Therapy Type
   5.4. Market Value Forecast By Therapy , 2015–2026
        5.4.1. Enzyme Replacement Therapy
        5.4.2. Stem-cell Therapy
        5.4.3. Substrate Reduction Therapy
        5.4.4. Others
   5.5. Market Attractiveness By Therapy

6. Global Lysosomal Storage Diseases Therapeutics Market Analysis and Forecasts, By Indication
   6.1. Introduction
   6.2. Basis Point Share (BPS) Analysis By Treatment Type
   6.3. Y-o-Y Growth Projections By Treatment Type
   6.4. Market Value Forecast By Indication , 2015–2026
        6.4.1. Gaucher's Disease
        6.4.2. Fabry Disease
        6.4.3. Pompe’s Syndrome
        6.4.4. Mucopolysaccharidosis
        6.4.5. Others
   6.5. Market Attractiveness By Indication

7. Global Lysosomal Storage Diseases Therapeutics Market Analysis and Forecasts, By End User
   7.1. Introduction
   7.2. Basis Point Share (BPS) Analysis By Treatment Type
   7.3. Y-o-Y Growth Projections By Treatment Type
   7.4. Market Value Forecast By End User , 2017–2027
   7.4.1. Hospitals
   7.4.2. Clinics
   7.5. Market Attractiveness By End User

8. Global Lysosomal Storage Diseases Therapeutics Market Analysis and Forecasts, By Region
   8.1. Basis Point Share (BPS) Analysis By Country
   8.2. Y-o-Y Growth Projections By Country
   8.3. Market Value Forecast By Region
        8.3.1. North America
        8.3.2. Latin America
        8.3.3. Europe
        8.3.4. Asia-Pacific (APAC)
        8.3.5. Middle East & Africa (MEA)
   8.4. Market Attractiveness By Country/Region

9. North America Lysosomal Storage Diseases Therapeutics Market Analysis and Forecast
   9.1. Introduction
        9.1.1. Basis Point Share (BPS) Analysis By Country
        9.1.2. Y-o-Y Growth Projections By Country
   9.2. Market Value Forecast By Country , 2015–2026
        9.2.1. US
        9.2.2. Canada
   9.3. Market Value Analysis and Forecast By Country & End User, 2015–2026
   9.4. Market Value Forecast By Type of Therapy , 2015–2026
        9.4.1. Enzyme Replacement Therapy
        9.4.2. Stem Cell Therapy
        9.4.3. Substrate Reduction Therapy
        9.4.4. Others
   9.5. Market Value Forecast By Indication , 2015–2026
        9.5.1. Gaucher's Disease
        9.5.2. Fabry Disease
        9.5.3. Pompe’s Syndrome
        9.5.4. Mucopolysaccharidosis
        9.5.5. Others
   9.6. Market Attractiveness Analysis
        9.6.4. By Country
        9.6.1. By Type of Therapy
        9.6.3. By Indication
        9.6.2. By End User
   9.7. Key Regulations
   9.8. Prominent Trends
   9.9. Drivers and Restraints: Impact Analysis

10. Latin America (LATAM) Lysosomal Storage Diseases Therapeutics Market Analysis and Forecast
   10.1. Introduction
        10.1.1. Basis Point Share (BPS) Analysis By Country
        10.1.2. Y-o-Y Growth Projections By Country
   10.2. Market Value Forecast By Country , 2015–2026
        10.2.1. Brazil
        10.2.2. Mexico
        10.2.3. Argentina
        10.2.4. Rest of LATAM
   10.3. Market Value Analysis and Forecast By Country & End User, 2015–2026
   10.4. Market Value Forecast By Type of Therapy , 2015–2026
        10.4.1. Enzyme Replacement Therapy
        10.4.2. Stem Cell Therapy
        10.4.3. Substrate Reduction Therapy
        10.4.4. Others
   10.5. Market Value Forecast By Indication , 2015–2026
        10.5.1. Gaucher's Disease
        10.5.2. Fabry Disease
        10.5.3. Pompe’s Syndrome
        10.5.4. Mucopolysaccharidosis
        10.5.5. Others
   10.6. Market Attractiveness Analysis
        10.6.4. By Country
        10.6.1. By Type of Therapy
        10.6.3. By Indication
        10.6.2. By End User
   10.7. Key Regulations
   10.8. Prominent Trends
   10.9. Drivers and Restraints: Impact Analysis

11. Europe Lysosomal Storage Diseases Therapeutics Market Analysis and Forecast
   11.1. Introduction
        11.1.1. Basis Point Share (BPS) Analysis By Country
        11.1.2. Y-o-Y Growth Projections By Country
   11.2. Market Value Forecast By Country , 2015–2026
        11.2.1. U.K.
        11.2.2. France
        11.2.3. Italy
        11.2.4. Spain
        11.2.5. Russia
   11.3. Market Value Forecast By Country& End User, 2015–2026
   11.4. Market Value Forecast By Type of Therapy , 2015–2026
        11.4.1. Enzyme Replacement Therapy
        11.4.2. Stem Cell Therapy
        11.4.3. Substrate Reduction Therapy
        11.4.4. Others
   11.5. Market Value Forecast By Indication , 2015–2026
        11.5.1. Gaucher's Disease
        11.5.2. Fabry Disease
        11.5.3. Pompe’s Syndrome
        11.5.4. Mucopolysaccharidosis
        11.5.5. Others
   11.6. Market Attractiveness Analysis
        11.6.4. By Country
        11.6.1. By Type of Therapy
        11.6.3. By Indication
        11.6.2. By End User
   11.7. Key Regulations
   11.8. Prominent Trends
   11.9. Drivers and Restraints: Impact Analysis

12. Asia-Pacific (APAC) Lysosomal Storage Diseases Therapeutics Market Analysis and Forecast
   12.1. Introduction
        12.1.1. Basis Point Share (BPS) Analysis By Country
        12.1.2. Y-o-Y Growth Projections By Country
   12.2. Market Value Forecast By Country , 2015–2026
        12.2.1. China
        12.2.2. Japan
        12.2.3. India
        12.2.4. Australia & New Zealand
        12.2.5. Rest of APAC
   12.3. Market Value Forecast By Country & End User, 2015–2026
   12.4. Market Value Forecast By Type of Therapy, 2015–2026
        12.4.1. Enzyme Replacement Therapy
        12.4.2. Stem Cell Therapy
        12.4.3. Substrate Reduction Therapy
        12.4.4. Others
   12.5. Market Value Forecast By Indication , 2015–2026
        12.5.1. Gaucher's Disease
        12.5.2. Fabry Disease
        12.5.3. Pompe’s Syndrome
        12.5.4. Mucopolysaccharidosis
        12.5.5. Others
   12.6. Market Attractiveness Analysis
        12.6.1. By Country
        12.6.2. By Type of Therapy
        12.6.3. By Indication
        12.6.4. By End User
   12.7. Key Regulations
   12.8. Prominent Trends
   12.9. Drivers and Restraints: Impact Analysis

13. Asia-Pacific (APAC) Lysosomal Storage Diseases Therapeutics Market Analysis and Forecast
   13.1. Introduction
        13.1.1. Basis Point Share (BPS) Analysis By Country
        13.1.2. Y-o-Y Growth Projections By Country
   13.2. Market Value Forecast By Country , 2015–2026
        13.2.1. GCC
        13.2.2. South Africa
        13.2.3. Rest of MEA
   13.3. Market Value Forecast By Country& End User, 2015–2026
   13.4. Market Value Forecast By Type of Therapy , 2015–2026
        13.4.1. Enzyme Replacement Therapy
        13.4.2. Stem Cell Therapy
        13.4.3. Substrate Reduction Therapy
        13.4.4. Others
   13.5. Market Value Forecast By Indication , 2015–2026
        13.5.1. Gaucher's Disease
        13.5.2. Fabry Disease
        13.5.3. Pompe’s Syndrome
        13.5.4. Mucopolysaccharidosis
        13.5.5. Others
   13.6. Market Attractiveness Analysis
        13.6.1. By Country
        13.6.2. By Type of Therapy
        13.6.3. By Indication
        13.6.4. By End User
   13.7. Key Regulations
   13.8. Prominent Trends
   13.9. Drivers and Restraints: Impact Analysis

14. Competition Landscape
   14.1.Competition Dashboard
   14.2.Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
        14.2.1. Shire PLC
        14.2.2. Pfizer, Inc. 
        14.2.3. Sanofi
        14.2.4. BioMarin Pharmaceutical Inc. 
        14.2.5. Actelion Ltd.
        14.2.6. Raptor Pharmaceutical Corp.
        14.2.7. Protalix Biotherapeutics Inc. 
        14.2.8. Amicus Therapeutics, Inc.

15. Assumptions and Acronyms Used

16. Research Methodology


List of Tables

Table 01: Global Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Type of Therapy, 2015–2026
Table 02: Global Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2026
Table 03: Global Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 04: Global Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Region, 2015–2026
Table 05: North America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 06: North America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 07: North America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Type of Therapy, 2015–2026
Table 08: North America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2026
Table 09: Latin America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 10: Latin America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 11: Latin America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Type of Therapy, 2015–2026
Table 12: Latin America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2026
Table 13: Europe Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 14: Europe Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Type of Therapy, 2015–2026
Table 15: Europe Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2026
Table 16: Europe Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 17: APAC Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 18: APAC Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Type of Therapy, 2015–2026
©2016 Persistence Market Research, All Rights Reserved 19
Table 19: APAC Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2026
Table 20: APAC Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 21: MEA Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 22: MEA Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Type of Therapy, 2015–2026
Table 23: MEA Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2026
Table 24: MEA Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026


List of Figures

Figure 01: Global Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026
Figure 02: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 03: Global Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By Type of Therapy, 2016 & 2026
Figure 04: Global Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By Type of Therapy, 2016–2026
Figure 05: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ opportunity By Enzyme Replacement Therapy Segment, 2016–2026
Figure 06: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ opportunity By Stem Cell Therapy Segment, 2016–2026
Figure 07: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ opportunity By Substrate reduction Therapy Segment, 2016–2026
Figure 08: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ opportunity By Others Segment, 2016–2026
Figure 09: Global Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Type of Therapy, 2016–2026
Figure 10: Global Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By Indication, 2016 & 2026
Figure 11: Global Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By Indication, 2016–2026
Figure 12: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity By Gaucher's Disease Indication Segment, 2016–2026
Figure 13: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity By Fabry Disease Indication Segment, 2016–2026
Figure 14: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity By Pompe’s Syndrome Indication Segment, 2016–2026
Figure 15: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity By Mucopolysaccharidosis Indication Segment, 2016–2026
Figure 16: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity By Others Indication Segment, 2016–2026
Figure 17: Global Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Indication, 2016–2026
Figure 18: Global Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By End User, 2016 & 2026
Figure 19: Global Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By End User, 2016–2026
Figure 20: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity By Hospitals End User Segment, 2016–2026
Figure 21: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity By Clinics End User Segment, 2016–2026
Figure 22: Global Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By End User, 2016–2026
Figure 23: Global Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By Region, 2016 & 2026
Figure 24: Global Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By Region, 2016–2026
Figure 25: North America Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 26: Latin America Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 27: Europe Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 28: Asia Pacific Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 29: MEA Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 30: Global Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Region, 2016–2026
Figure 31: North America Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By Country, 2016 & 2026
Figure 32: North America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 33: North America Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By Country, 2016–2026
Figure 34: The U.S. Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 35: Canada Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 36: North America Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Country, 2016–2026
Figure 37: North America Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Type of Therapy, 2016–2026
Figure 38: North America Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Indication, 2016–2026
Figure 39: North America Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By End User, 2016–2026
Figure 40: Latin America Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By Country, 2016 & 2026
Figure 41: Latin America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 42: Latin America Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By Country, 2016–2026
Figure 43: Brazil Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 44: Mexico Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 45: Argentina Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 46: Rest of Latin America Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 47: Latin America Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Country, 2016–2026
Figure 48: Latin America Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Type of Therapy, 2016–2026
Figure 49: Latin America Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Indication, 2016–2026
Figure 50: Latin America Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By End User, 2016–2026
Figure 51: Europe Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By Country, 2016 & 2026
Figure 52: Europe Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 53: Europe Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By Country, 2016–2026
Figure 54: Germany Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 55: France Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 56: U.K. Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 57: Spain Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 58: Italy Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 59: Russia Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 60: Rest of Europe Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 61: Europe Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Country, 2016–2026
Figure 62: Europe Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Type of Therapy, 2016–2026
Figure 63: Europe Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Indication, 2016–2026
Figure 64: Europe Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By End User, 2016–2026
Figure 65: APAC Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By Country, 2016 & 2026
Figure 66: APAC Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 67: APAC Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By Country, 2016–2026
Figure 68: China Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 69: Japan Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 70: India Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 71: Australia & New Zealand Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 72: Rest of APAC Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 73: APAC Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Country, 2016–2026
Figure 74: APAC Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Type of Therapy, 2016–2026
Figure 75: APAC Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Indication, 2016–2026
Figure 76: APAC Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By End User, 2016–2026
Figure 77: MEA Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By Country, 2016 & 2026
Figure 78: MEA Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 79: MEA Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By Country, 2016–2026
Figure 80: GCC Countries Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 81: South Africa Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 82: Rest of MEA Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 83: MEA Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Country, 2016–2026
Figure 84: MEA Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Type of Therapy, 2016–2026
Figure 85: MEA Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Indication, 2016–2026
Figure 86: MEA Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By End User, 2016–2026